Medicine and Dentistry
Hematologic Malignancy
100%
Hematopoietic Stem Cell Transplantation
80%
Chronic Myelogenous Leukemia
80%
Disease
70%
Allogeneic Stem Cell Transplantation
40%
Knockout Model
40%
B-Cell Chronic Lymphocytic Leukemia
40%
Overall Survival
31%
Paroxysmal Nocturnal Hemoglobinuria
27%
Hematopoiesis
26%
Drug Therapy
26%
Autologous Hematopoietic Stem Cell Transplantation
26%
Glycosylphosphatidylinositol Anchored Protein
26%
Transplantation
23%
Mycophenolic Acid
20%
Conditioning
20%
Antibiotics
20%
Chronic Myelogenous Leukemia
20%
Consolidation Chemotherapy
20%
Human Immunodeficiency Virus
20%
Emergency Medical Technician
20%
Hodgkin's Lymphoma
20%
High Risk Population
20%
Autologous Stem Cell Transplantation
20%
Chromosome 22
20%
Lymphadenopathy
20%
Allogenic Bone Marrow Transplantation
20%
Erythropoiesis
20%
Febrile Neutropenia
20%
Downregulation
20%
Chronic Graft Versus Host Disease
20%
Hyperglycemia
20%
Thiotepa
20%
Embryoid Body
20%
Chromosome 9
20%
Antiinfective Agent
20%
Drug Megadose
20%
Scoring System
20%
Pure Red Cell Aplasia
20%
West Nile Virus
20%
Virus Encephalitis
20%
Oncology
20%
Hematopoietic Stem Cell
20%
Advance Care Planning
20%
Leukemia
17%
Arm
16%
Low Risk Population
16%
Engraftment
13%
Antiretroviral Therapy
13%
Reverse-Transcriptase Inhibitor
13%
Keyphrases
Clinical Trials
24%
Consolidation Chemotherapy
20%
Clinical Practice Guidelines
20%
Mycophenolate Mofetil
20%
Medication Prescribing
20%
Prescribing Errors
20%
Outcome-based
20%
Primary Management
20%
Acute Promyelocytic Leukemia
20%
Hodgkin Disease
20%
Chromosome 22
20%
Graft-versus-host Disease (GvHD)
20%
Refractory Hodgkin Lymphoma
20%
Prognostic Model
20%
Ph Chromosome
20%
Erythropoiesis
20%
Allogeneic Bone Marrow Transplantation
20%
Erythrocyte Membrane Proteins
20%
Corticosteroid Therapy
20%
Adult Human Mesenchymal Stem Cells
20%
High-dose Therapy
20%
Myelodysplastic Syndrome
20%
Intercellular Transfer
20%
Paroxysmal Nocturnal Hemoglobinuria
20%
Prognostic Scoring System
20%
CD33
20%
Molecular Remission
20%
Gemtuzumab Ozogamicin
20%
Calicheamicin
20%
Chromosome 9
20%
Chronic Myeloid Leukemia
20%
11q23 Deletion
20%
Disease Outcome
20%
Oncology
20%
West Nile Encephalitis
20%
GRP94
20%
West Nile Virus Infection
20%
Initial Treatment
20%
Chronic Lymphocytic Leukemia
20%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
20%
Hematopoietic Stem Cells
20%
Pure Red Cell Aplasia
20%
High-risk Population
16%
Low-risk Group
12%
Thrombocytopenia
10%
Therapeutic Agents
10%
Risky Driving
10%
Practice Guidelines
10%
Fatty Acid Acylation
10%
Rh Antigens
10%
Biochemistry, Genetics and Molecular Biology
Hematopoiesis
60%
Fanconi Anemia, Complementation Group C
40%
Knockout Model
40%
Embryoid Body
36%
Hematopoietic Stem Cell
35%
Phosphatidylinositol
26%
Mouse
22%
Hyperglycemia
20%
Protein C
20%
Chromosome 22
20%
Glycosylphosphatidylinositol
20%
Autologous Stem Cell Transplantation
20%
Extract
20%
Transgenic Mouse
20%
Drug Megadose
20%
DNA Library
20%
Eicosanoid Receptor
20%
Erethism
20%
Ribozyme
20%
Hematopoietic Stem Cell Transplantation
20%
Cell Culture
20%
Yeast Two-Hybrid Screening
20%
Cell Lysate
20%
Chromosome 9
20%
West Nile Virus
20%
Myeloid Nuclear Differentiation Antigen
20%
B Cell
20%
Deletion Mutant
20%
Autologous Hematopoietic Stem Cell Transplantation
16%
High Risk Population
16%
Embryonic Stem Cell
15%
Glycosyl
13%
Low Risk Population
12%
Bone Marrow Failure
12%
Overall Survival
10%
Upregulation
10%
Rhesus Antigen
10%
Knockout Mouse
10%
Cell Death
10%
Progression Free Survival
8%
X Chromosomal Inheritance
6%
thought
6%
Surface Property
6%
Therapeutic Protein
6%
Mouse Model
5%
Rho(D) Immune Globulin
5%
Glycophorin
5%
Enzyme
5%
ABL (Gene)
5%
Anabolism
5%
